ARIEL3 Clinical Trial
An Investigational Drug for Advanced Ovarian Cancer
ARIEL3 (NCT# 01968213) is a Phase 3 trial designed to evaluate the effect of rucaparib as maintenance treatment following platinum-based therapy in women with platinum-sensitive, relapsed, high grade serous or endometrioid ovarian fallopian tube, or primary peritoneal cancer. The biomarker results from the ARIEL2 study will be applied to the analysis of results in this study.
Participating in the ARIEL3 Clinical Trial
The purpose of the ARIEL3 study is to compare the effects of the investigational drug rucaparib versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer. The effects of rucaparib versus standard of care will be evaluated in defined groups of patients based on their biomarker test.
Two thirds of the participants enrolled in this study will receive rucaparib. The other third of participants will receive placebo. Because the study is double-blind, neither physicians nor participants will know whether they are receiving rucaparib or placebo.
If you qualify for the ARIEL3 trial, you will receive the following as part of the study: study-related physical exams, lab tests results including BRCA and the other biomarker tests, the study medication (rucaparib or placebo).